The cost of an intravenous drug used to treat lead poisoning has skyrocketed after a 2700% price increase by Valeant Pharmaceuticals. Experts worry that its high price and the lack of alternatives ...

For a few weeks in January, Valeant Pharmaceuticals '(NYSE: VRX) stock outperformed the S&P 500 index. The run didn't last long, though. Here's why Valeant's rebound quickly fizzled. The first phase ...

Valeant Pharmaceutical's shares are down 78 percent YTD. Shares have been in a slump in the last two months, without any reason. Consensus price target sits at $52. Are investors making a mistake here ...

The chief executive of embattled Valeant Pharmaceuticals, J. Michael Pearson, has agreed to be deposed by a Senate committee investigating the causes of soaring prescription medicine prices. Meanwhile ...

The lawsuit claims the company targeted minority women and children despite being aware of the risk of asbestos in talc. By Tiffany Hsu The world’s most prestigious consulting firm has a secretive $12 ...

Little more than a year since Valeant Pharmaceuticals International, Inc. (NYSE: VRX) announced its acquisition of Raleigh-based Sprout Pharmaceuticals for $1 billion, former Sprout shareholders are ...

Valeant Pharmaceuticals this month agreed to delay the launch of efinaconazole, a drug for treating a nail fungal condition, until after an arbitration hearing in ...

Controversial pharma company Valeant signaled Monday it expects to dispose of a business associated with large drug price increases and foresees much more modest price hikes in the future. Valeant ...